Lilly's TRIUMPH-2 Phase 3 Data Show Retatrutide Cuts Weight and A1C in Type 2 Diabetes and Obesity

Trial design and key efficacy endpoints

Eli Lilly disclosed detailed results from TRIUMPH-2, a Phase 3 trial evaluating retatrutide, an investigational GIP, GLP-1 and glucagon triple hormone receptor agonist, in adults with type 2 diabetes and obesity or overweight. At 80 weeks, all three retatrutide doses produced substantial reductions in both body weight and A1C. Participants taking the 4 mg, 9 mg and 12 mg doses lost an average of 29.8 lbs (12.7%), 45.4 lbs (19.1%) and 49.6 lbs (20.8%), respectively.

Glycemic and cardiometabolic outcomes

The trial also reported meaningful improvements in glycemic control and cardiovascular risk factors. Participants on retatrutide 9 mg and 12 mg reduced their A1C by an average of 1.6% and 1.5%, respectively, versus 1.4% for the 4 mg dose, with up to 40.0% of participants reaching an A1C below 5.7%, the threshold considered normal blood sugar. The highest dose was associated with average reductions of 39.5% in triglycerides, 19.6% in non-HDL cholesterol, 10.8 mmHg in systolic blood pressure, 6.7 inches in waist circumference and 58.3% in high-sensitivity C-reactive protein.

High-BMI subgroup and obesity remission

Outcomes were most pronounced in participants with higher baseline body mass index. Among those with a baseline BMI of 35 or higher, participants taking retatrutide 12 mg lost an average of 60.8 lbs (23.4%), and by the end of the study 59.5% of participants on the 12 mg dose no longer met the BMI criteria for obesity, suggesting the threshold-crossing could position retatrutide as a potential obesity-remission therapy rather than only a weight-management drug.

Regulatory path and forthcoming data

Lilly said it plans to submit a Biologics License Application to the U.S. Food and Drug Administration in the first quarter of 2027. The detailed results were presented at the 62nd Annual Meeting of the European Association for the Study of Diabetes in Milan and were simultaneously published in The Lancet. Additional results from the obstructive sleep apnea arm within TRIUMPH-2 will be presented at a future medical meeting and published in a peer-reviewed journal, making the sleep apnea readout the next verifiable milestone on retatrutide's disclosure calendar.

Pipeline and broader context

Retatrutide sits inside a broader Lilly cardiometabolic pipeline that already includes the approved incretin therapies Mounjaro and Zepbound, and the TRIUMPH-2 disclosure follows separate, positive Phase 3 findings for Lilly's Foundayo 17.2 mg, signaling a multi-asset push across obesity, diabetes and related comorbidities as the company prepares its Q1 2027 filing.